expenses was 1,719 MTHB, increased by 546 MTHB or 47% from 2016. This increment was mainly from the loss on written-off and disposal of plant and equipments and intangible assets of Solvay Biochemicals
liquidity and to reduce the financial burden. The selling value is 40.48 % when compares to total assets from company consolidated statements. (Market Value 70,370,000.00 x 100 divided by total assets as at
Mar 2017 Amount % Amount % Assets Current Assets Cash and cash equivalents 237.54 10.37% 237.45 10.45% Short-term investment 3.73 0.16% 21.35 0.94% Account receivable, trade and others 728.08 31.80
was mainly from the higher in gross margin. 4 (Unit: Baht million) Consolidated balance sheets As at 31st Mar 2018 As at 31st Mar 2017 Amount % Amount % Assets Current Assets Cash and cash equivalents
As at 30th Jun 2018 As at 31st Mar 2018 Amount % Amount % Assets Current Assets Cash and cash equivalents 522.37 20.68% 488.97 20.70% Short-term investment 4.36 0.18% 4.85 0.21% Account receivable
proportion in Associate Company and benefit to the Company and shareholders in the future. The transaction mentioned above is considered as acquisition of assets in accordance with the Notification of the
subsidiary, please kindly find the following attachment. Please kindly be informed accordingly. Yours faithfully, Mr. Geza Emil Perlaki Managing Director For period ended 31 March 2020 MANAGEMENT DISCUSSION
\(Microsoft Word - 7 \\270\\244.60 _Eng_.doc\) December 7 th , 2017 To : Managing Director The Stock Exchange of Thailand Re : The Disposition of Land in subsidiary company The board of directors
: T.K.S. Technologies Public Company Limited (“The Company”) Buyer of the Share : Mr.Jutiphan Mongkolsuthree Relationship with the Company: Mr.Jutiphan Mongkolsuthree Director and Managing Director of